Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.64
CVD's Cash to Debt is ranked higher than
62% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.05 vs. CVD: 2.64 )
CVD' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 2.64

Equity to Asset 0.65
CVD's Equity to Asset is ranked higher than
70% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. CVD: 0.65 )
CVD' s 10-Year Equity to Asset Range
Min: 0.26   Max: 0.75
Current: 0.65

0.26
0.75
Interest Coverage 32.45
CVD's Interest Coverage is ranked higher than
57% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.50 vs. CVD: 32.45 )
CVD' s 10-Year Interest Coverage Range
Min: 2.2   Max: 788.72
Current: 32.45

2.2
788.72
F-Score: 6
Z-Score: 5.98
M-Score: -2.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 8.37
CVD's Operating margin (%) is ranked higher than
81% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.76 vs. CVD: 8.37 )
CVD' s 10-Year Operating margin (%) Range
Min: 2.33   Max: 14.43
Current: 8.37

2.33
14.43
Net-margin (%) 6.91
CVD's Net-margin (%) is ranked higher than
81% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. CVD: 6.91 )
CVD' s 10-Year Net-margin (%) Range
Min: 1.66   Max: 10.78
Current: 6.91

1.66
10.78
ROE (%) 11.45
CVD's ROE (%) is ranked higher than
82% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.60 vs. CVD: 11.45 )
CVD' s 10-Year ROE (%) Range
Min: 5.33   Max: 25.33
Current: 11.45

5.33
25.33
ROA (%) 7.01
CVD's ROA (%) is ranked higher than
83% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. CVD: 7.01 )
CVD' s 10-Year ROA (%) Range
Min: 1.98   Max: 11.32
Current: 7.01

1.98
11.32
ROC (Joel Greenblatt) (%) 20.58
CVD's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. CVD: 20.58 )
CVD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.96   Max: 33.12
Current: 20.58

4.96
33.12
Revenue Growth (%) 13.00
CVD's Revenue Growth (%) is ranked higher than
87% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. CVD: 13.00 )
CVD' s 10-Year Revenue Growth (%) Range
Min: -1.7   Max: 17.7
Current: 13

-1.7
17.7
EBITDA Growth (%) 40.40
CVD's EBITDA Growth (%) is ranked higher than
96% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. CVD: 40.40 )
CVD' s 10-Year EBITDA Growth (%) Range
Min: -21.9   Max: 40.4
Current: 40.4

-21.9
40.4
EPS Growth (%) 43.80
CVD's EPS Growth (%) is ranked higher than
95% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. CVD: 43.80 )
CVD' s 10-Year EPS Growth (%) Range
Min: -26.9   Max: 64.9
Current: 43.8

-26.9
64.9
» CVD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CVD Guru Trades in Q3 2013

Louis Moore Bacon 10,000 sh (New)
Vanguard Health Care Fund 2,246,400 sh (unchged)
Chuck Royce 323,000 sh (unchged)
Ron Baron 300,000 sh (unchged)
Steven Cohen Sold Out
Caxton Associates Sold Out
RS Investment Management Sold Out
James Barrow 741,076 sh (-0.81%)
Paul Tudor Jones 5,900 sh (-31.4%)
» More
Q4 2013

CVD Guru Trades in Q4 2013

Jim Simons 87,000 sh (New)
Steven Cohen 6,221 sh (New)
Joel Greenblatt 9,619 sh (New)
Paul Tudor Jones 161,200 sh (+2632.2%)
Vanguard Health Care Fund 2,246,400 sh (unchged)
Ron Baron 300,000 sh (unchged)
Chuck Royce 323,000 sh (unchged)
Louis Moore Bacon Sold Out
James Barrow 729,776 sh (-1.52%)
» More
Q1 2014

CVD Guru Trades in Q1 2014

Jim Simons 189,018 sh (+117.26%)
Joel Greenblatt 12,886 sh (+33.96%)
Chuck Royce 323,000 sh (unchged)
Vanguard Health Care Fund 2,246,400 sh (unchged)
Ron Baron 300,000 sh (unchged)
Steven Cohen Sold Out
James Barrow 725,755 sh (-0.55%)
Paul Tudor Jones 7,300 sh (-95.47%)
» More
Q2 2014

CVD Guru Trades in Q2 2014

Ken Fisher 25,621 sh (New)
Joel Greenblatt 356,011 sh (+2662.77%)
Paul Tudor Jones 15,836 sh (+116.93%)
Vanguard Health Care Fund 2,486,000 sh (+10.67%)
Ron Baron 300,000 sh (unchged)
James Barrow 701,680 sh (-3.32%)
Chuck Royce 293,000 sh (-9.29%)
Jim Simons 169,100 sh (-10.54%)
» More
» Details

Insider Trades

Latest Guru Trades with CVD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Add 2662.77%0.37%$81.55 - $106.04 $ 83.97-6%356011
Joel Greenblatt 2014-03-31 Add 33.96%0.01%$86.85 - $105.69 $ 83.97-15%12886
Joel Greenblatt 2013-12-31 New Buy0.02%$83.45 - $90.51 $ 83.97-3%9619
Vanguard Health Care Fund 2013-06-30 Add 317.31%0.48%$71.21 - $78.88 $ 83.9712%2246400
Vanguard Health Care Fund 2013-03-31 New Buy0.16%$57.77 - $74.32 $ 83.9725%538300
Joel Greenblatt 2012-09-30 Sold Out 0.13%$46.39 - $49.24 $ 83.9776%0
James Barrow 2012-09-30 New Buy0.07%$46.39 - $49.24 $ 83.9776%785725
Joel Greenblatt 2012-06-30 Add 53.73%0.05%$44.42 - $47.81 $ 83.9782%38072
Ron Baron 2012-03-31 Reduce -50%0.09%$43.31 - $49.24 $ 83.9793%300000
Joel Greenblatt 2011-12-31 Add 23.51%0.03%$43.43 - $52.9 $ 83.9779%26917
Ray Dalio 2011-12-31 Sold Out 0.03%$43.43 - $52.9 $ 83.9779%0
Joel Greenblatt 2011-09-30 Add 143.35%0.1%$44.79 - $62.26 $ 83.9759%21794
Ray Dalio 2011-09-30 New Buy0.03%$44.79 - $62.26 $ 83.9759%45737
Joel Greenblatt 2011-06-30 Reduce -63.28%0.25%$55.92 - $62.6 $ 83.9742%8956
George Soros 2011-06-30 Sold Out $55.92 - $62.6 $ 83.9742%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.40
CVD's P/E(ttm) is ranked higher than
78% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CVD: 26.40 )
CVD' s 10-Year P/E(ttm) Range
Min: 11.14   Max: 63.04
Current: 26.4

11.14
63.04
P/B 2.90
CVD's P/B is ranked higher than
71% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.38 vs. CVD: 2.90 )
CVD' s 10-Year P/B Range
Min: 1.68   Max: 5.52
Current: 2.9

1.68
5.52
P/S 1.83
CVD's P/S is ranked higher than
78% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.42 vs. CVD: 1.83 )
CVD' s 10-Year P/S Range
Min: 1.14   Max: 3.81
Current: 1.83

1.14
3.81
PFCF 21.42
CVD's PFCF is ranked higher than
82% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CVD: 21.42 )
CVD' s 10-Year PFCF Range
Min: 13.3   Max: 1392.29
Current: 21.42

13.3
1392.29
EV-to-EBIT 18.92
CVD's EV-to-EBIT is ranked higher than
81% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CVD: 18.92 )
CVD' s 10-Year EV-to-EBIT Range
Min: 7.7   Max: 97.9
Current: 18.92

7.7
97.9
PEG 2.51
CVD's PEG is ranked higher than
89% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CVD: 2.51 )
CVD' s 10-Year PEG Range
Min: 0.64   Max: 77.1
Current: 2.51

0.64
77.1
Shiller P/E 34.11
CVD's Shiller P/E is ranked higher than
88% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CVD: 34.11 )
CVD' s 10-Year Shiller P/E Range
Min: 15.26   Max: 50.9
Current: 34.11

15.26
50.9
Current Ratio 2.81
CVD's Current Ratio is ranked higher than
67% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. CVD: 2.81 )
CVD' s 10-Year Current Ratio Range
Min: 0.78   Max: 2.81
Current: 2.81

0.78
2.81
Quick Ratio 2.72
CVD's Quick Ratio is ranked higher than
74% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. CVD: 2.72 )
CVD' s 10-Year Quick Ratio Range
Min: 0.71   Max: 2.72
Current: 2.72

0.71
2.72

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 28.66
CVD's Price/Net Current Asset Value is ranked higher than
64% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CVD: 28.66 )
CVD' s 10-Year Price/Net Current Asset Value Range
Min: 13.45   Max: 614.43
Current: 28.66

13.45
614.43
Price/Tangible Book 3.10
CVD's Price/Tangible Book is ranked higher than
78% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. CVD: 3.10 )
CVD' s 10-Year Price/Tangible Book Range
Min: 2.04   Max: 14.66
Current: 3.1

2.04
14.66
Price/DCF (Projected) 1.85
CVD's Price/DCF (Projected) is ranked higher than
85% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CVD: 1.85 )
CVD' s 10-Year Price/DCF (Projected) Range
Min: 1.19   Max: 6.35
Current: 1.85

1.19
6.35
Price/Median PS Value 0.96
CVD's Price/Median PS Value is ranked higher than
72% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. CVD: 0.96 )
CVD' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 1.81
Current: 0.96

0.29
1.81
Price/Peter Lynch Fair Value 3.86
CVD's Price/Peter Lynch Fair Value is ranked higher than
86% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CVD: 3.86 )
CVD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.72   Max: 7.44
Current: 3.86

0.72
7.44
Price/Graham Number 1.92
CVD's Price/Graham Number is ranked higher than
82% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CVD: 1.92 )
CVD' s 10-Year Price/Graham Number Range
Min: 1.04   Max: 4.26
Current: 1.92

1.04
4.26
Earnings Yield (Greenblatt) 5.30
CVD's Earnings Yield (Greenblatt) is ranked higher than
58% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. CVD: 5.30 )
CVD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 13
Current: 5.3

1
13
Forward Rate of Return (Yacktman) 8.46
CVD's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. CVD: 8.46 )
CVD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7.7   Max: 20.9
Current: 8.46

-7.7
20.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:CVD.Germany
Covance, Inc is a Delaware Corporation. It is a drug development services company providing a range of early-stage and late-stage product development services on a worldwide basis mainly to the pharmaceutical, biotechnology and medical device industries. It also provides laboratory testing services to the chemical, agrochemical and food industries. Its two reportable segments are early development services, which include discovery support services, preclinical services and clinical pharmacology services; and late-stage development services, which include central laboratory, Phase II-IV clinical development, and market access services. The Company's preclinical services include toxicology services, pharmaceutical chemistry and related services. The Company's preclinical area has been a source of innovation by introducing new technologies for client access to data such as StudyTracker, electronic animal identification, multimedia study reports and animal and test tube measures of induced cell proliferation or reproduction. The Company's preclinical toxicology services include in vivo toxicology studies, which are studies of the effects of drugs in animals, genetic toxicology studies, which include studies of the effects of drugs on chromosomes, as well as on genetically modified mice and other specialized toxicology services. In its pharmaceutical chemistry services, it determines the metabolic profile and bioavailability of drug candidates. It also provides laboratory testing services to the chemical, agricultural chemical and food industries. The Company offers a complete range of services to agricultural chemical manufacturers to determine the potential risk to humans, animals and the environment from plant protection products such as pesticides. In its nutritional chemistry services, the Company offers a range of services to the food, nutriceutical and animal feed industries, including nutritional analysis and equivalency, nutritional content fact labels, microbiological and chemical contaminant safety analysis, pesticide screening and stability testing. It provides custom polyclonal and monoclonal antibody services for research purposes and purpose-bred animals for biomedical research. The Company provides optimization services including custom immunology and antibody services, metabolism studies and pharmacokinetic screening as well as non-GLP toxicology, in vivo pharmacology, imaging services and biomarker services. The Company's bioanalytical testing services helps determine the appropriate dose and frequency of drug application from late discovery evaluation through Phase III clinical testing on a full-scale, globally integrated basis. The Company provides clinical pharmacology services, including first-in-human trials, of new pharmaceuticals at its seven clinics located throughout the United States and its one clinic in Leeds, United Kingdom and also offer its clients access to specialized patient populations needed for P
» More Articles for CVD

Headlines

Articles On GuruFocus.com
Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
Parexcel: Great Growth but a Tough Business Aug 17 2011 
Covance Inc. Reports Operating Results (10-K) Feb 28 2011 
Covance Inc. (CVD) Executive Vice President & COO Wendel Barr sells 13,000 Shares Dec 21 2010 
Covance Inc. (CVD) Executive Vice President & COO Wendel Barr sells 31,300 Shares Dec 15 2010 
Covance Inc. (CVD) Executive Vice President & COO Wendel Barr sells 19,305 Shares Nov 22 2010 
Weekly Guru Bargains Highlights: SD, CREE, AMLN, ICLR, CVD Nov 07 2010 
Covance Inc. Reports Operating Results (10-Q) Nov 05 2010 
Weekly Guru Bargains Highlights: Whirlpool Corp, Plexus Corp, Pulte Homes Inc, Owens Corning, Covanc Sep 18 2010 
Weekly CEO Buys Highlight: Dynex Capital Inc, Helix Energy Solutions Group Inc, Superior Energy Serv Aug 08 2010 


More From Other Websites
Covance Retains Balanced View on Steady Growth Aug 22 2014
Contract Researcher Parexel Sees Growth In Biotech Aug 21 2014
COVANCE INC Financials Aug 08 2014
Dr. Phillip P. Chan, the CEO and President of CytoSorbents Corporation (CTSO), Interviews with The... Aug 01 2014
COVANCE INC Files SEC form 10-Q, Quarterly Report Aug 01 2014
Covance Earnings Beat, Revenues Meet Estimates, View Tweaked Jul 31 2014
Covance (CVD) Showing Signs Of Being Water-Logged And Getting Wetter Jul 30 2014
Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2014 Financial Results Conference... Jul 30 2014
COVANCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 30 2014
Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2014 Financial Results Conference... Jul 30 2014
Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of... Jul 29 2014
Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of... Jul 29 2014
Q2 2014 Covance Earnings Release - After Market Close Jul 29 2014
Covance Increases its Medical and Scientific Leadership with Two Senior-Level Appointments Jul 09 2014
/C O R R E C T I O N -- Covance Inc./ Jul 02 2014
/C O R R E C T I O N -- Covance Inc./ Jul 02 2014
Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2014 Financial Results Conference... Jun 25 2014
Strength Seen in Covidien (CVD): Stock Soars 20.5% Jun 17 2014
Covance To Present At The William Blair 34th Annual Growth Stock Conference Jun 09 2014
Covance To Present At The Goldman Sachs 35th Annual Global Healthcare Conference Jun 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide